Alzheimer'S Disease is a progressive neurodegenerative disorder characterized by the gradual loss of neuronal function. This page provides comprehensive information about the disease, including its pathophysiology, clinical presentation, diagnosis, and current therapeutic approaches. [1]
Alzheimer's disease (AD) is the most common cause of dementia, characterized by progressive cognitive decline, memory loss, and behavioral changes. It is a neurodegenerative disorder that primarily affects older adults, with prevalence doubling every 5 years after age 65. Approximately 6.5 million Americans aged 65 and older live with AD, making it a major public health challenge worldwide. [2]
The Hippocampal Neurogenesis pathway is impaired in AD, contributing to memory deficits. Adult hippocampal neurogenesis declines with age and is further reduced in Alzheimer's Disease due to amyloid toxicity, neuroinflammation, and reduced neurotrophic support. [3]
Cerebral Amyloid Angiopathy pathway involvement is common in AD, with Aβ deposition in cerebral blood vessels contributing to hemorrhagic strokes and impaired vascular clearance of amyloid. [4]
The Wnt/β-Catenin Signaling pathway plays a critical role in synaptic plasticity and neuroprotection; its dysregulation contributes to amyloidogenesis and tau pathology. [5]
Histone Modification pathways are altered in AD, with global histone acetylation changes affecting gene expression patterns related to memory and neuronal survival. [6]
The MAPT V337M mutation provides insight into tau pathophysiology. Multi-omic analysis of iPSC-derived neurons with this mutation revealed perturbations in axonogenesis pathways and unexpected decreases in tau phosphorylation compared to wild-type neurons, highlighting the complex relationship between tau mutations and downstream molecular changes. [7]
The amyloid cascade hypothesis proposes that Aβ accumulation is the primary driver of AD pathogenesis:
Figure: Amyloid cascade hypothesis — from genetic and environmental triggers through Aβ accumulation and downstream cascades to clinical disease progression.
| Biomarker | Sample | Change in AD | Earliest Detection | Clinical Use |
|---|---|---|---|---|
| Aβ42/40 ratio | CSF | ↓ Decreased | 15–20 years before symptoms | AT(N) classification |
| p-tau181 | CSF / Plasma | ↑ Increased | 10–15 years before symptoms | Tau pathology staging |
| p-tau217 | Plasma | ↑ Increased | 10–15 years before symptoms | Screening (high accuracy) |
| Total tau | CSF | ↑ Increased | 5–10 years before symptoms | Neurodegeneration marker |
| NfL | CSF / Plasma | ↑ Increased | 5–10 years before symptoms | Neurodegeneration severity |
| GFAP | Plasma | ↑ Increased | 10+ years before symptoms | Astrocyte reactivity |
| Amyloid PET | Brain imaging | Positive | 15–20 years before symptoms | Amyloid plaque burden |
| Tau PET | Brain imaging | Positive | 5–10 years before symptoms | Tangle distribution (Braak) |
Cellular models derived from patient stem cells and genetic studies have advanced understanding of Alzheimer's Disease pathogenesis:
Alzheimer's disease typically progresses through several distinct stages, from preclinical to severe dementia:
Anti-tau therapeutics represent the next generation of disease-modifying treatments for Alzheimer's disease, targeting the tau pathology that closely correlates with cognitive decline. Key approaches include monoclonal antibodies, antisense oligonucleotides, and small-molecule inhibitors.
| Drug | Company | Target | Status |
|---|---|---|---|
| E2814 (Etalanetug) | Eisai | MTBR (p-tau396/404) | Phase III |
| Bepranemab | UCB | aa 235-250 | Phase II |
| JNJ-63733657 | Janssen | p-tau217 | Phase II |
| Posdinemab | Bristol Myers Squibb | Mid-domain | Phase II |
| Semorinemab | Roche | N-terminus | Phase II |
| PRX005 | Prothena | MTBR | Phase I |
| Gosuranemab | Biogen | N-terminal | Discontinued (Phase II) |
| Tilavonemab | AbbVie | N-terminal | Discontinued (Phase II) |
| Zagotenemab | Eli Lilly | MC1 epitope | Discontinued (Phase II) |
| Drug | Company | Mechanism | Status |
|---|---|---|---|
| BIIB080 (MAPTRx) | Biogen/Ionis | MAPT mRNA knockdown | Phase II |
| NIO752 | Roche | MAPT mRNA knockdown | Phase I |
| Drug | Company | Mechanism | Status |
|---|---|---|---|
| LY3372689 (Oglemilide) | Eli Lilly | OGA inhibitor | Phase II |
| ASN90 | Asceneuron | OGA inhibitor | Phase II |
| LMTM (TRx0237) | TauRx | Aggregation inhibitor | Phase III |
| Drug | Company | Target | Status |
|---|---|---|---|
| AADvac1 | Axon Neuroscience | Phosphorylated tau | Phase II |
| ACI-35 | AC Immune | p-tau396/404 | Phase Ib/IIa |
See Anti-Tau Therapeutics for detailed rankings and clinical trial data.
Brain-computer interfaces represent an emerging therapeutic approach for Alzheimer's disease, focusing on cognitive enhancement, memory restoration, and monitoring disease progression.
For a comprehensive list of companies developing AD therapeutics, see AD Pipeline Companies. Key companies include:
The study of Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Despite significant advances in understanding Alzheimer's Disease (AD) pathogenesis, several fundamental questions remain unresolved. These knowledge gaps represent active areas of investigation and opportunity for future research.
What is the precise sequence of events in preclinical AD?: While amyloid-beta accumulation is thought to initiate the disease process, the exact sequence of cellular events leading from normal aging to clinically manifest dementia remains incompletely characterized. Understanding the temporal relationship between amyloid, tau, synaptic loss, and neurodegeneration is critical for timing therapeutic interventions.
Why do some individuals with amyloid plaques never develop dementia?: Population studies reveal a significant subset of individuals with neuropathological AD hallmarks who maintain normal cognitive function. The biological mechanisms underlying this resilience—termed cognitive reserve—require further investigation to inform protective strategies.
What drives the selective vulnerability of specific neuronal populations?: Certain brain regions (hippocampus, entorhinal cortex, basal forebrain) show early and severe neurodegeneration in AD, while others are relatively preserved. The molecular basis for this selective vulnerability is not fully understood.
Can blood biomarkers reliably detect preclinical AD?: While plasma p-tau217 and other blood-based biomarkers show promise, standardization across platforms and validation in diverse populations remains incomplete. The field needs accessible, inexpensive biomarkers for population screening.
What biomarker combinations best predict progression?: Individual biomarkers provide limited prognostic information. Developing composite biomarker panels that accurately predict conversion from mild cognitive impairment to AD dementia would improve clinical trial design and patient counseling.
Why do amyloid-targeting therapies show limited clinical benefit?: Despite successful amyloid clearance, clinical trials have shown modest effects on cognitive decline. This suggests that amyloid reduction alone may be insufficient, or that treatment is initiated too late in the disease process. Understanding the relationship between amyloid removal and downstream tau pathology is crucial.
How can we effectively target tau pathology?: Tau aggregation correlates more strongly with cognitive decline than amyloid, yet tau-targeted therapies have proven challenging. Developing effective tau-modifying treatments requires better understanding of tau propagation mechanisms and optimal treatment windows.
What is the role of neuroinflammation in AD progression?: Microglial activation is a hallmark of AD, but whether it represents a protective or deleterious response remains contested. Clarifying the causal role of neuroinflammation could open new therapeutic avenues.
What are the real-world outcomes of amyloid-targeting antibodies?: Lecanemab and donanemab have received regulatory approval, but real-world effectiveness data across diverse populations remains limited. Understanding long-term outcomes, optimal treatment duration, and combination strategies is critical for clinical implementation.
Can combination therapy approaches improve outcomes over monotherapy?: Given the modest effects of amyloid clearance alone, combining anti-amyloid with anti-tau, anti-inflammatory, or synaptic protective approaches may yield greater clinical benefit. What are the optimal sequencing and combinatorial strategies?
How can biomarker-defined subtypes guide personalized treatment?: Emerging data suggests different therapeutic responses based on biomarker profiles (e.g., tau burden, APOE status). How should treatment selection be personalized based on molecular subtype?
What is the therapeutic potential of TREM2 modulators?: TREM2 variants strongly influence AD risk, and TREM2-activating antibodies are in development. What is the optimal timing and patient selection for TREM2-targeted therapy?
How do we address tau pathology beyond antibody approaches?: Small molecule tau aggregation inhibitors, antisense oligonucleotides, and gene therapy approaches are in development. Which modality offers the best balance of brain penetration, efficacy, and safety?
Which lifestyle interventions provide meaningful risk reduction?: Epidemiological studies suggest that cognitive reserve, physical activity, and cardiovascular health modifiers may reduce AD risk. However, the magnitude of effect and mechanisms underlying these associations require validation in rigorous clinical trials.
How should AD risk be communicated and acted upon?: Developing effective strategies for risk communication and behavioral modification could enable primary prevention approaches before neurodegenerative processes become established.
Combination Biomarker Panels for Alzheimer's Disease## Recent Research
Alpha-7 Nicotinic Acetylcholine Receptor Neuroprotection: Research has demonstrated that sinomenine attenuates AD pathology through alpha7 nAChR-mediated neuroprotection, inhibiting oxidative stress and Abeta-induced neuronal damage. This adds to the growing evidence for alpha7 nAChR as a therapeutic target in AD.[8]
Novel Blood-Based Proteomic Signatures: Durcan R et al. (2025) evaluated multiplex proteomic methods for detecting Alzheimer's, Lewy body, and frontotemporal dementia biomarkers. This approach offers less invasive diagnostic options compared to cerebrospinal fluid analysis[9].
Metal Ions in Neurodegeneration: Chen L et al. (2025) reviewed the involvement of iron, manganese, copper, and zinc in AD pathogenesis, highlighting potential therapeutic targets for metal homeostasis modulation[10].
Mendelian Randomization Study: Belbasis L et al. (2025) identified novel protein associations with AD using genetic data, providing insights into disease mechanisms and potential biomarkers[11].
Global Neurodegeneration Proteomics Consortium: Imam F et al. (2025) conducted large-scale biomarker and drug target discovery across neurodegenerative diseases through collaborative proteomics[12].
Ginsenosides Neuroprotective Effects: Jiang M et al. (2025) reviewed the neuroprotective effects of ginsenosides Rg1, Rb1 and rare ginsenosides as promising candidate agents for both Parkinson's disease and Alzheimer's disease, providing insights into network pharmacology and potential therapeutic applications[13].
Vitamin D and Neurodegeneration: Savran Z et al. (2025) reviewed the role of vitamin D in the etiopathogenesis of neurodegenerative diseases including multiple sclerosis, Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis, highlighting its potential as a modifiable risk factor[14].
Diabetes and Neurodegeneration: Szablewski L (2025) reviewed the associations between diabetes mellitus as a major risk factor for cognitive decline, dementia, Parkinson's disease, and Alzheimer's disease, highlighting the importance of metabolic health in neurodegeneration[8:1].
Neuronal overexpression of Nrf2 reduces dystrophic neurites in 5XFAD Alzheimer's disease model mice (2026) - Nrf2 transcription factor overexpression in neurons reduces amyloid-induced dystrophic neurites, suggesting antioxidant pathway activation as therapeutic strategy[15]
Mitochondrial Carbonic Anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models (2026) - CA-VB inhibition improves mitochondrial function in brain endothelial cells and restores memory in AD mouse models[16]
Seizures drive tau propagation in a tauopathy mouse model (2026) - Epileptic activity accelerates tau pathology spread, linking network hyperexcitability to tau propagation[17]
Loss of neuronal population organization links pathology to behavior in a model of Alzheimer's disease (2026) - Alzheimer's pathology disrupts neuronal population coding organization, correlating with behavioral deficits[18]
Digital therapeutics represent an emerging frontier in Alzheimer's and Parkinson's disease management. A comprehensive 2026 review examined current trends and future perspectives for digital interventions in neurodegeneration, including cognitive training apps, wearable monitoring devices, and AI-powered diagnostic tools[19].
A comprehensive 2026 review analyzed current and potential biomarkers for Alzheimer's disease, Parkinson's disease, and ALS. Key findings include:
Recent advances in Alzheimer's disease research include:
Recent publications have advanced our understanding of Alzheimer's disease mechanisms and therapeutic approaches:
The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) has published guidance on harmonizing Alzheimer's disease biomarker practices, addressing variability in fluid biomarker measurements across laboratories[15:1].
The COSMIC collaboration study found that disturbing dreams (nightmares) are associated with increased dementia incidence in adults aged 60-89, suggesting sleep disturbances as a potential early marker of neurodegeneration[16:1].
Research has demonstrated that physical exercise provides cognitive benefits through the adiponectin-PP2A pathway, which protects against chronic stress-induced tau hyperphosphorylation in the hippocampus. This mechanism provides molecular justification for exercise interventions in AD prevention[17:1].
Chronic cerebral hypoperfusion has been shown to exacerbate amyloid and tau pathology by impairing glymphatic transport through AQP4- and VEGF-mediated pathways, highlighting the importance of vascular health in AD progression[18:1].
New PET tracer methods using [(125)I]IPPI and [(125)I]IBETA autoradiography have been validated for detecting tau protein and amyloid plaques in postmortem human brains of Down Syndrome and Alzheimer's disease patients[19:1].
Jack CR Jr, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia. 2018. ↩︎ ↩︎
Scheltens P, et al. Alzheimer's disease. Lancet. 2021. ↩︎ ↩︎
Masters CL, et al. Alzheimer's disease. Nature Reviews Disease Primers. 2025. ↩︎ ↩︎
van der Kant R, et al. Amyloid-β-independent regulators of tau pathology in Alzheimer disease. Nature Reviews Neuroscience. 2020. ↩︎ ↩︎
Sims JR, et al. Donanemab in early Alzheimer's disease. JAMA. 2023. ↩︎ ↩︎
Cullen NC, et al. Blood biomarkers for Alzheimer's disease. Molecular Psychiatry. 2024. ↩︎ ↩︎
Mohl GA, et al. Multi-omic phenotyping of MAPT V337M neurons reveals early changes in axonogenesis and tau phosphorylation. bioRxiv. 2026. ↩︎ ↩︎
Szablewski L. Associations Between Diabetes Mellitus and Neurodegenerative Diseases. 2025. ↩︎ ↩︎
Durcan R et al. Multiplex proteomic methods in neurodegenerative dementias. Alzheimer's & Dementia. 2025. ↩︎ ↩︎
Chen L et al. Metal ions in neurodegenerative diseases. Signal Transduction and Targeted Therapy. 2025. ↩︎ ↩︎
Belbasis L et al. Mendelian randomization identifies proteins related to neurodegenerative diseases. Brain. 2025. ↩︎ ↩︎
Imam F et al. Global Neurodegeneration Proteomics Consortium. Nature Medicine. 2025. ↩︎ ↩︎
Jiang M et al. Ginsenosides Rg1, Rb1 and rare ginsenosides: Promising candidate agents for Parkinson's disease and Alzheimer's disease. 2025. ↩︎ ↩︎
Savran Z et al. Vitamin D and Neurodegenerative Diseases. 2025. ↩︎ ↩︎
Sadleir KR et al. Neuronal overexpression of Nrf2 reduces dystrophic neurites in 5XFAD Alzheimer's disease model mice. 2026. ↩︎ ↩︎
Lemon NL et al. Mitochondrial Carbonic Anhydrase-VB inhibition rescues brain endothelial stress and memory in Alzheimer's disease models. 2026. ↩︎ ↩︎
Barbour AJ et al. Seizures drive tau propagation in a tauopathy mouse model. 2026. ↩︎ ↩︎
Ruff DA et al. Loss of neuronal population organization links pathology to behavior in a model of Alzheimer's disease. 2026. ↩︎ ↩︎
Jeong YJ et al. Digital Therapeutics for Alzheimer's and Parkinson's Diseases. JAD (2026). 2026. ↩︎ ↩︎
Peng J et al. Current potential biomarkers for AD, PD and ALS. Ageing Res Rev (2026). 2026. ↩︎